Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amidephrine (also known as amidefrine) is a selective alpha1-adrenergic receptor agonist and sympathomimetic agent. It acts primarily as a vasoconstrictor and is used topically as a nasal decongestant for the treatment of allergic, acute, chronic, and vasomotor rhinitis. Amidephrine is structurally related to phenethylamines and is typically administered as its mesylate salt (amidephrine mesylate or amidefrine mesilate). Its main mechanism of action involves stimulation of alpha1-adrenoceptors in vascular smooth muscle, leading to vasoconstriction and reduced nasal congestion. As of 2000, it was marketed only in Austria[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amidephrine.